New Zealand (NZ) industry opposition to licensing "unconvincing"
This article was originally published in Clinica
New Zealand's Ministry of Health finds medical device industry objections to the proposed introduction of product licensing "unconvincing". In a new report analysing comments submitted following last year's discussion paper on regulatory reform, the Ministry contends that the industry "did not advance any reasoned argument why the proposals would not work or why an alternative scenario would work better".
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.